Press Releases

Aeras and UCLA Announce License Deal for New TB Vaccine

May 3, 2005 - The Aeras Global TB Vaccine Foundation of Bethesda, MD and The University of California, Los Angeles (UCLA) announced today that the two organizations had executed a non-exclusive license for a tuberculosis vaccine technology developed at UCLA.

Denmark Becomes First European Country to Support Aeras Foundation’s TB Vaccine Development Efforts

April 26, 2005 - Denmark today became the first European country to support the Aeras Global TB Vaccine Foundation's efforts to develop a new, effective tuberculosis vaccine with announcements of new financial commitments and scientific partnerships. The agreements, announced today in Copenhagen at an update on TB vaccine development, strengthen Denmark's continuing role in the fight against TB.

Aeras and Statens Serum Institut Enter into Collaboration Agreement to Develop TB Vaccine

March 29, 2005 - The Aeras Global TB Vaccine Foundation of Bethesda, Maryland and Statens Serum Institut (SSI) of Copenhagen, Denmark, today announced a new collaboration on the pre-clinical and clinical development of SSI's tuberculosis (TB) vaccine, HyVac4.

Jerald Sadoff M.D. Named CEO of TB Vaccine Effort

September 17, 2004 - The Aeras Global TB Vaccine Foundation, formerly known as the Sequella Global Tuberculosis Foundation, has named Jerald C. Sadoff, M.D., the former Clinical Director for Vaccine Development at Merck, as its new Chief Executive Officer. In addition to its new name and new leadership, Aeras also announced a new scientific focus on TB vaccine development. This will leave the development of new TB drugs and diagnostics to other organizations, with which Aeras will collaborate. The announcements were made at TBV 2003, a global tuberculosis vaccine research conference in Montreal.